Developing a broad pipeline of precision dermatology products


Program Areas & Pipeline

Azitra is using its Microbiome Dermatology Platform to develop products to improve skin appearance and treat skin diseases through three program areas:


Program Area #1: Consumer Products

Azitra’s technology can be applied to address many consumer needs related to skin appearance. Such products will be applied as topical ointments and creams to address conditions including: dry, red, flaky or inflammed skin.

Azitra and Bayer have formed a joint development program targeted at harnessing the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin. To learn more about the collaboration, read the press release here.


Program Area #2: Live BioTherapeutic Products (LBP’s) for Treating Skin Disease

Azitra is using the natural commensal bacteria Staphylococcus epidermidis (SE) from the skin microbiome to develop bioengineered microbiome products for the treatment of skin disease.



Program Area #3: Advanced Technology Indications based on the Microbiome

Azitra has received grant funding from U.S. Department of Defense (DoD) and other agencies to develop advanced microbiome products for military, public health and consumer applications. The overall program includes candidates that target Staph aureus (including MRSA) to reduce potential for mosquito biting and consequently reduce the potential of mosquitos to promote disease vectoring. The Company is also studying the use of commensal bacteria for use as biosensors which may have application in targeting adverse organisms that may attack the skin and potentially for use to counter bio-hazards.